Journal
HEART FAILURE REVIEWS
Volume 26, Issue 6, Pages 1505-1514Publisher
SPRINGER
DOI: 10.1007/s10741-020-09959-3
Keywords
Epigenetics; Cardiac hypertrophy; Methylation; Acetylation; Non-coding RNA
Categories
Funding
- National Nature Scientific Funding of China [81672264, 81871858]
Ask authors/readers for more resources
Cardiac hypertrophy is a significant risk factor for cardiovascular disease, with epigenetic mechanisms playing an important role and offering therapeutic potential. Research indicates that both embryonic and functional genes are regulated by epigenetic mechanisms during cardiac hypertrophy, potentially serving as therapeutic targets.
Cardiac hypertrophy is a significant risk factor for cardiovascular disease, including heart failure, arrhythmia, and sudden death. Cardiac hypertrophy involves both embryonic gene expression and transcriptional reprogramming, which are tightly regulated by epigenetic mechanisms. An increasing number of studies have demonstrated that epigenetics plays an influential role in the occurrence and development of cardiac hypertrophy. Here, we summarize the latest research progress on epigenetics in cardiac hypertrophy involving DNA methylation, histone modification, and non-coding RNA, to help understand the mechanism of epigenetics in cardiac hypertrophy. The expression of both embryonic and functional genes can be precisely regulated by epigenetic mechanisms during cardiac hypertrophy, providing a substantial number of therapeutic targets. Thus, epigenetic treatment is expected to become a novel therapeutic strategy for cardiac hypertrophy. According to the research performed to date, epigenetic mechanisms associated with cardiac hypertrophy remain far from completely understood. Therefore, epigenetic mechanisms require further exploration to improve the prevention, diagnosis, and treatment of cardiac hypertrophy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available